Lates News

According to Every Day Economic News, Pacific Securities released a research report on August 29th, giving a buy rating to Haoyuan Medicine (688131.SH). The rating reasons mainly include: 1) rapid growth of front-end business, continuous expansion of product categories; 2) stable growth of back-end business, rapid growth in hand orders.